Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   SANJAY MATHEW   and   BRITTANY O'BRIEN.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            5.901
         
        
        
     
 
    
        
        - 
            Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
            
            
                Score: 0.873
             
- 
            Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
            
            
                Score: 0.811
             
- 
            An Update on Community Ketamine Practices. Am J Psychiatry. 2022 05; 179(5):393-394.
            
            
                Score: 0.785
             
- 
            Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
            
            
                Score: 0.725
             
- 
            The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel). 2019 Sep 11; 12(3).
            
            
                Score: 0.654
             
- 
            Bayesian adaptive randomization trial of intravenous ketamine for veterans with late-life, treatment-resistant depression. Contemp Clin Trials Commun. 2019 12; 16:100432.
            
            
                Score: 0.651
             
- 
            Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 Oct; 48(11):1699.
            
            
                Score: 0.216
             
- 
            Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
            
            
                Score: 0.210
             
- 
            Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
            
            
                Score: 0.192
             
- 
            Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
            
            
                Score: 0.186
             
- 
            Impulsivity and Suicidal Behavior. Curr Top Behav Neurosci. 2020; 47:179-195.
            
            
                Score: 0.167
             
- 
            Psychotherapy for Mixed Depression and Mixed Mania. Psychiatr Clin North Am. 2020 03; 43(1):199-211.
            
            
                Score: 0.166
             
- 
            A Proof-of-Mechanism Study to Test Effects of the NMDA Receptor Antagonist Lanicemine on Behavioral Sensitization in Individuals With Symptoms of PTSD. Front Psychiatry. 2019; 10:846.
            
            
                Score: 0.166
             
- 
            Interacting immediate and long-term action regulation in suicidal behavior. J Mood Anxiety Disord. 2025 Jun; 10:100118.
            
            
                Score: 0.060
             
- 
            Interactions of immediate and long-term action regulation in the course and complications of bipolar disorder. Philos Trans R Soc Lond B Biol Sci. 2019 02 18; 374(1766):20180132.
            
            
                Score: 0.039